$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000145368723000052 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$5.249M	$5.938M
YoY Change	-86.63%	-82.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.105M	$5.695M
YoY Change	-2.02%	2.85%
% of Gross Profit
Research & Development	$17.78M	$18.62M
YoY Change	-7.3%	5.29%
% of Gross Profit
Depreciation & Amortization	$200.0K	$200.0K
YoY Change	0.0%	100.0%
% of Gross Profit
Operating Expenses	$23.89M	$24.32M
YoY Change	-6.0%	4.71%
Operating Profit	-$18.64M	-$18.38M
YoY Change	-234.47%	-270.62%
Interest Expense	$752.0K	$808.0K
YoY Change	5.17%	14.29%
% of Operating Profit
Other Income/Expense, Net	$245.0K	$255.0K
YoY Change		65.58%
Pretax Income	-$11.39M	-$21.66M
YoY Change	-232.39%	-175.28%
Income Tax
% Of Pretax Income
Net Earnings	-$11.39M	-$21.66M
YoY Change	-232.39%	-175.28%
Net Earnings / Revenue	-216.94%	-364.82%
Basic Earnings Per Share	-$0.07	-$0.14
Diluted Earnings Per Share	-$0.07	-$0.14
COMMON SHARES
Basic Shares Outstanding	153.4M shares	153.3M shares
Diluted Shares Outstanding	153.4M	153.3M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$112.0M	$125.9M
YoY Change	-21.14%	7.23%
Cash & Equivalents	$112.0M	$125.9M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$4.258M	$3.785M
YoY Change	-34.71%	-30.17%
Inventory
Prepaid Expenses
Receivables	$5.385M	$6.839M
Other Receivables	$1.055M	$1.843M
Total Short-Term Assets	$122.7M	$138.4M
YoY Change	-28.88%	6.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.593M	$2.765M
YoY Change	-8.47%	2.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Other Assets	$1.413M	$1.335M
YoY Change	-0.84%	-8.81%
Total Long-Term Assets	$16.78M	$17.30M
YoY Change	8.29%	10.27%
TOTAL ASSETS
Total Short-Term Assets	$122.7M	$138.4M
Total Long-Term Assets	$16.78M	$17.30M
Total Assets	$139.5M	$155.7M
YoY Change	-25.82%	6.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$267.0K	$1.063M
YoY Change	-61.47%	302.65%
Accrued Expenses	$12.90M	$9.347M
YoY Change	4.33%	5.15%
Deferred Revenue	$4.234M	$4.232M
YoY Change	-73.49%	-84.88%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.24M	$10.22M
YoY Change	211.57%	1368.1%
Total Short-Term Liabilities	$29.37M	$26.53M
YoY Change	-13.02%	-32.4%
LONG-TERM LIABILITIES
Long-Term Debt	$13.79M	$16.23M
YoY Change	-39.09%	-35.2%
Other Long-Term Liabilities	$30.90M	$38.36M
YoY Change	-26.53%	49.57%
Total Long-Term Liabilities	$44.69M	$54.58M
YoY Change	-30.92%	7.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.37M	$26.53M
Total Long-Term Liabilities	$44.69M	$54.58M
Total Liabilities	$74.06M	$81.11M
YoY Change	-24.79%	-9.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$428.0M	-$416.6M
YoY Change	8.92%	3.75%
Common Stock	$15.00K	$15.00K
YoY Change	0.0%	25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.45M	$74.58M
YoY Change
Total Liabilities & Shareholders Equity	$139.5M	$155.7M
YoY Change	-25.82%	6.86%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$11.39M	-$21.66M
YoY Change	-232.39%	-175.28%
Depreciation, Depletion And Amortization	$200.0K	$200.0K
YoY Change	0.0%	100.0%
Cash From Operating Activities	-$9.895M	-$8.765M
YoY Change	-19.36%	-26.12%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$130.0K
YoY Change	-112.12%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$28.25M
YoY Change		182.54%
Cash From Investing Activities	-$12.00K	$28.12M
YoY Change	-87.88%	194.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.586M	$149.0K
YoY Change	-107.01%	-91.38%
NET CHANGE
Cash From Operating Activities	-9.895M	-$8.765M
Cash From Investing Activities	-12.00K	$28.12M
Cash From Financing Activities	-2.586M	$149.0K
Net Change In Cash	-12.49M	$19.49M
YoY Change	-150.98%	-3243.06%
FREE CASH FLOW
Cash From Operating Activities	-$9.895M	-$8.765M
Capital Expenditures	$12.00K	$130.0K
Free Cash Flow	-$9.907M	-$8.895M
YoY Change	-18.61%	-27.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37798
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Selecta Biosciences, Inc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1622110
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	65 Grove Street,
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	923-1400
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	SELB
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	153426983	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125925000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106438000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28164000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6839000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6596000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1843000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	3162000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3785000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3778000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	138392000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	148138000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2765000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2794000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11201000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11617000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	24000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	26000	usd
CY2023Q1	us-gaap	Assets Assets	155693000	usd
CY2022Q4	us-gaap	Assets Assets	165886000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1063000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	316000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9347000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14084000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	10218000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	8476000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1671000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1608000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4232000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	593000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26531000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25077000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	16228000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	17786000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9617000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10055000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5519000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23219000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	19140000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	81114000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	72058000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153426983	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153426983	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153042435	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153042435	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	495733000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	493308000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-416600000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394937000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4569000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4558000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	74579000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	93828000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155693000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165886000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5938000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33999000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18624000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17689000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5695000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5537000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	24319000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	23226000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18381000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	10773000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1331000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	15000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	19000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	28000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	808000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	707000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4079000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18515000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	255000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	154000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-32000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21674000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28746000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153345554	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124232799	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153345554	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127573485	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	93828000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	149000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2276000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	74579000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22521000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	127000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1675000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-79000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2753000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-32000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	55764000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	206000	usd
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	351000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	79000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	416000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	293000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	147000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2276000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2753000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	398000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	383000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4079000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18515000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	243000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2761000	usd
CY2023Q1	selb	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	-1319000	usd
CY2022Q1	selb	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-853000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	747000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-281000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-281000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9158000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-26890000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5359000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2222000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8765000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11864000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	28254000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	10000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	130000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	455000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28124000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9545000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	110000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	149000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	127000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	149000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1728000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-29000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19487000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-620000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108038000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115436000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127525000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114816000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	625000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	494000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	48000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000	usd
CY2023Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	0	usd
CY2022Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	94000	usd
CY2023Q1	selb	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	127500000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1600000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28175000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28164000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	28778000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	usd
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	18515000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21663000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21663000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	10263000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10263000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153345554	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124232799	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3340686	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153345554	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127573485	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	289000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54432928	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15585436	shares
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125925000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113437000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127525000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114816000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14084000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8157000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7999000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5392000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5205000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2765000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2794000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2206000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4242000	usd
CY2023Q1	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	594000	usd
CY2022Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	696000	usd
CY2023Q1	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4724000	usd
CY2022Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	7274000	usd
CY2023Q1	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	1132000	usd
CY2022Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	985000	usd
CY2023Q1	selb	Accrued Interest Current AccruedInterestCurrent	215000	usd
CY2022Q4	selb	Accrued Interest Current AccruedInterestCurrent	222000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	476000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	665000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9347000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	696000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	506000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	142000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	220000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	255000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	586000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	729000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2015000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2740000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2818000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2902000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2990000	usd
CY2023Q1	selb	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	946000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14411000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3123000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11288000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	653000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	457000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31228279	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.53
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	61828652	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2276000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2753000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9800000	usd
CY2022Q4	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	593000	usd
CY2023Q1	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	10500000	usd
CY2023Q1	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	-1342000	usd
CY2023Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	9751000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	593000	usd
CY2023Q1	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	10500000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1342000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9751000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	62400000	usd
CY2023Q1	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P2Y
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd

Files In Submission

Name	View Source	Status
0001453687-23-000052-index-headers.html	Edgar Link	pending
0001453687-23-000052-index.html	Edgar Link	pending
0001453687-23-000052.txt	Edgar Link	pending
0001453687-23-000052-xbrl.zip	Edgar Link	pending
exhibit311_3312023.htm	Edgar Link	pending
exhibit312_3312023.htm	Edgar Link	pending
exhibit321_3312023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20230331.htm	Edgar Link	pending
selb-20230331.xsd	Edgar Link	pending
selb-20230331_g1.jpg	Edgar Link	pending
selb-20230331_g2.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
selb-20230331_cal.xml	Edgar Link	unprocessable
selb-20230331_def.xml	Edgar Link	unprocessable
selb-20230331_pre.xml	Edgar Link	unprocessable
selb-20230331_lab.xml	Edgar Link	unprocessable
selb-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2023 Q2 Form 10-Q Financial Statement

#000145368723000052 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2023 Q2 Form 10-Q Financial Statement

#000145368723000052 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac